Dr. David Lieberman discusses the Geneoscopy: Efficacy of Non-Invasive Colorectal Cancer Screening Test Evaluated in the CRC-PREVENT Phase 3 Trial
“As leaders, we have a responsibility to come together to impact cancer. Colorectal cancer is one of the most preventable and treatable cancers when diagnosed
“Embrace your flaws: Everyone has flaws. I feel that I have been successful because I am able to recognize these flaws, understand where I need
ST. LOUIS, Feb. 28, 2023 /PRNewswire/ Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of Don Hardison to its board of
FDA’s Decision Forthcoming for Innovative Test with Agency’s Breakthrough Device Designation ST. LOUIS, Jan. 24, 2023 / — Geneoscopy, Inc., a life sciences company focused
Colorectal Cancer and Advanced Adenoma Sensitivity Results are the Highest Reported from any Prospective Pivotal Study for a Noninvasive Screening Test Innovative RNA Biomarker Screening
Adds CAP Accreditation to Clinical Laboratory Improvement Amendments (CLIA) certification ST. LOUIS, Dec. 14, 2022 / — Geneoscopy, Inc., a life sciences company focused on
Originally published July 1, 2022 Haytham Gareer, MD, PhD, MBA, FACS for Pharmacy Times Nearly 63% of newly diagnosed patients have advanced colorectal cancer,
New look matches focus on transforming GI health ST. LOUIS, MISSOURI (October 3, 2022) | Geneoscopy today announced a corporate rebrand and launch. The rebranding
